ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri
|
|
|
Glucose 6-phosphate Dehydrogenase Deficiency
Mehmet Emin Büyükokuroğlu*, Halis Süleyman*
* Dr., Atatürk Üniversitesi Tıp Fakültesi Farmakoloji AD, Erzurum
Glucose 6-phosphate dehydrogenase (D-glucose 6-phosphate: NADP+ oxidoreductase, EC 1.1.1.49; G6PD) is the key enzyme which catalyzes first step of hexose mono phosphate metabolic pathway. Unique source of NADPH in erythrocyte is the hexose mono phosphate metabolic pathway and synthesis of NADPH decreases in G6PD deficiency. The most important defect in hexose mono phosphate metabolic pathway is that due to glucose 6-phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is inherited X-linked recessive. This disease is widely prevalent throughout the world, approximately 400 million poeple are affected. G6PD is necessary to maintain to reduced glutathione level in erythrocytes. Therefore, these cells have been protected to oxidative stress. In affected person, hemolysis occurs in older red blood cells after exposure to some drugs (primaquine, aspirin, sulfonamides), chemicals (methylen blue, naphthelene) and fava beans. Anemia, hemoglobinemia, hemoglobinuria, back pain, jaundice and reticulocytosis develop. Specific enzyme assays are the best diagnostic test.Keywords: Glucose 6-phosphate dehydrogenase deficiency,
Drug, PharmacogeneticTurkiye Klinikleri J Med Sci 2001, 21:415-419
|
|
|
|
|
